RESUMEN
Rhodococcus equi (R. equi) is a zoonotic opportunistic pathogen that mainly causes fatal lung and extrapulmonary abscesses in foals and immunocompromised individuals. To date, no commercial vaccine against R. equi exists. We previously screened all potential vaccine candidates from the complete genome of R. equi using a reverse vaccinology approach. Five of these candidates, namely ABC transporter substrate-binding protein (ABC transporter), penicillin-binding protein 2 (PBD2), NlpC/P60 family protein (NlpC/P60), esterase family protein (Esterase), and M23 family metallopeptidase (M23) were selected for the evaluation of immunogenicity and immunoprotective effects in BALB/c mice model challenged with R. equi. The results showed that all five vaccine candidate-immunized mice experienced a significant increase in spleen antigen-specific IFN-γ- and TNF-α-positive CD4 + and CD8 + T lymphocytes and generated robust Th1- and Th2-type immune responses and antibody responses. Two weeks after the R. equi challenge, immunization with the five vaccine candidates reduced the bacterial load in the lungs and improved the pathological damage to the lungs and livers compared with those in the control group. NlpC/P60, Esterase, and M23 were more effective than the ABC transporter and PBD2 in inducing protective immunity against R. equi challenge in mice. In addition, these vaccine candidates have the potential to induce T lymphocyte memory immune responses in mice. In summary, these antigens are effective candidates for the development of protective vaccines against R. equi. The R. equi antigen library has been expanded and provides new ideas for the development of multivalent vaccines.
Asunto(s)
Infecciones por Actinomycetales , Vacunas Bacterianas , Modelos Animales de Enfermedad , Inmunidad Humoral , Ratones Endogámicos BALB C , Rhodococcus equi , Animales , Rhodococcus equi/inmunología , Rhodococcus equi/genética , Ratones , Vacunas Bacterianas/inmunología , Vacunas Bacterianas/administración & dosificación , Infecciones por Actinomycetales/prevención & control , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/microbiología , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/inmunología , Inmunidad Celular , Femenino , Pulmón/microbiología , Pulmón/inmunología , Pulmón/patología , Carga Bacteriana , Proteínas Bacterianas/inmunología , Proteínas Bacterianas/genética , Interferón gamma/inmunología , Interferón gamma/metabolismoRESUMEN
Rhodococcus equi is a major cause of foal pneumonia and an opportunistic pathogen in immunocompromised humans. While alveolar macrophages constitute the primary replicative niche for R. equi, little is known about how intracellular R. equi is sensed by macrophages. Here, we discovered that in addition to previously characterized pro-inflammatory cytokines (e.g., Tnfa, Il6, Il1b), macrophages infected with R. equi induce a robust type I IFN response, including Ifnb and interferon-stimulated genes (ISGs), similar to the evolutionarily related pathogen, Mycobacterium tuberculosis. Follow up studies using a combination of mammalian and bacterial genetics demonstrated that induction of this type I IFN expression program is largely dependent on the cGAS/STING/TBK1 axis of the cytosolic DNA sensing pathway, suggesting that R. equi perturbs the phagosomal membrane and causes DNA release into the cytosol following phagocytosis. Consistent with this, we found that a population of ~12% of R. equi phagosomes recruits the galectin-3,-8 and -9 danger receptors. Interestingly, neither phagosomal damage nor induction of type I IFN require the R. equi's virulence-associated plasmid. Importantly, R. equi infection of both mice and foals stimulates ISG expression, in organs (mice) and circulating monocytes (foals). By demonstrating that R. equi activates cytosolic DNA sensing in macrophages and elicits type I IFN responses in animal models, our work provides novel insights into how R. equi engages the innate immune system and furthers our understanding how this zoonotic pathogen causes inflammation and disease.
Asunto(s)
Infecciones por Actinomycetales/inmunología , Inmunidad Innata/inmunología , Interferón Tipo I/inmunología , Macrófagos/inmunología , Rhodococcus equi/inmunología , Animales , Citosol/inmunología , ADN/inmunología , Femenino , Enfermedades de los Caballos/inmunología , Caballos , Masculino , RatonesRESUMEN
The efficacy of transfusion with hyperimmune plasma (HIP) for preventing pneumonia caused by Rhodococcus equi remains ill-defined. Quarter Horse foals at 2 large breeding farms were randomly assigned to be transfused with 2 L of HIP from adult donors hyperimmunized either with R. equi (RE HIP) or a conjugate vaccine eliciting antibody to the surface polysaccharide ß-1â6-poly-N-acetyl glucosamine (PNAG HIP) within 24 hours of birth. Antibody activities against PNAG and the rhodococcal virulence-associated protein A (VapA), and to deposition of complement component 1q (CÕ1q) onto PNAG were determined by ELISA, and then associated with either clinical pneumonia at Farm A (n = 119) or subclinical pneumonia at Farm B (n = 114). Data were analyzed using multivariable logistic regression. Among RE HIP-transfused foals, the odds of pneumonia were approximately 6-fold higher (P = 0.0005) among foals with VapA antibody activity ≤ the population median. Among PNAG HIP-transfused foals, the odds of pneumonia were approximately 3-fold (P = 0.0347) and 11-fold (P = 0.0034) higher for foals with antibody activities ≤ the population median for PNAG or CÕ1q deposition, respectively. Results indicated that levels of activity of antibodies against R. equi antigens are correlates of protection against both subclinical and clinical R. equi pneumonia in field settings. Among PNAG HIP-transfused foals, activity of antibodies with CÕ1q deposition (an indicator of functional antibodies) were a stronger predictor of protection than was PNAG antibody activity alone. Collectively, these findings suggest that the amount and activity of antibodies in HIP (i.e., plasma volume and/or antibody activity) is positively associated with protection against R. equi pneumonia in foals.
Asunto(s)
Acetilglucosamina/inmunología , Infecciones por Actinomycetales/veterinaria , Anticuerpos Antibacterianos/uso terapéutico , Proteínas Bacterianas/inmunología , Enfermedades de los Caballos/prevención & control , Inmunización Pasiva/veterinaria , Neumonía Bacteriana/veterinaria , Rhodococcus equi/inmunología , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/microbiología , Infecciones por Actinomycetales/prevención & control , Animales , Animales Recién Nacidos/inmunología , Animales Recién Nacidos/microbiología , Anticuerpos Antibacterianos/inmunología , Femenino , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Caballos/inmunología , Caballos/microbiología , Inmunización Pasiva/métodos , Masculino , Neumonía Bacteriana/inmunología , Neumonía Bacteriana/microbiología , Neumonía Bacteriana/prevención & controlRESUMEN
Equine theileriosis, caused by the Theileria equi protozoan, is a disease of worldwide importance. T. equi expresses surface proteins, of which the EMA-2 protein is a promising antigen for vaccine use. The aim of this study was to evaluate the immune response of adult horses, pregnant mares, and foals to an experimental EMA-2 protein of recombinant T. equi vaccine. A total of 46 horses were used in this study for vaccine trials and challenges. Twelve geldings, 14 pregnant mares, and 14 foals were divided into vaccinated and control groups. Total serum specific anti-rEMA-2 IgG, IgG subclasses, and transcription of cytokines related to the immune response were evaluated. For the vaccine challenge, six six-month-old foals were divided into vaccinated and control groups. For the challenge, blood from a horse with theileriosis was transfused to the foals. Geldings and pregnant mares maintained anti-rEMA-2 IgG levels at 130 and 140 days after vaccination, respectively. The most-detected IgG subclasses in vaccinated were IgG3/5, IgG4/7, and IgG1. IL2, IL10, IL12, IL17, IFN-γ, and TNF-α were the most-transcribed cytokines in PBMCs of vaccinated horses stimulated with rEMA-2. Challenge with T. equi demonstrated that vaccinated foals had an increase of 33% in total IgG four days after blood transfusion, while control foals had no significant response, suggesting that vaccine antibodies may have recognized EMA-2 protein of the native T. equi antigen. T. equi recombinant EMA-2 was shown to be a promising vaccine antigen by inducing humoral and cellular immunity similar to that observed in natural parasite infections.
Asunto(s)
Vacunas Bacterianas , Enfermedades de los Caballos , Inmunidad , Rhodococcus equi , Theileria , Animales , Femenino , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/prevención & control , Caballos , Masculino , Embarazo , Proteínas Recombinantes , Rhodococcus equi/inmunología , Theileria/inmunologíaRESUMEN
In order to better understand the influence of age on innate immune function in horses, blood was collected from twelve adult horses (aged 10-16 years; mean: 13 years) and ten geriatric horses (aged 18-26 years; mean: 21.7 years) for analysis of plasma myeloperoxidase, complete blood counts, and cytokine and receptor expression in response to in vitro stimulation with heat-inactivated Rhodococcus equi, heat-inactivated Escherichia coli, and PMA/ionomycin. Gene expression was measured using RT-PCR for IFNγ, IL-1ß, IL-6, IL-8, IL-10, IL-12α, IL-13, IL-17α, TLR2, TLR4, and TNFα. Endocrine function and body weight were measured to assess any potential impacts of ACTH, insulin, or body weight on immune function; none of the horses had pituitary pars intermedia dysfunction. The geriatric horse group had lower concentrations of plasma myeloperoxidase (P = 0.0459) and lower absolute monocyte counts (P = 0.0477); however, the difference in monocyte counts was no longer significant after outliers were removed. Additionally, only two significant differences in cytokine/receptor expression in whole blood were observed. Compared with adult horses, the geriatric horses had increased TNFα expression after in vitro stimulation with heat-inactivated R. equi (P = 0.0224) and had decreased IL-17α expression after PMA/ionomycin stimulation when one outlier was excluded (P = 0.0334). These changes may represent a compensatory mechanism by which geriatric horses could ensure adequate immune responses despite potentially dysfunctional neutrophil activity and/or decreased monocyte counts. Aging may influence equine innate immune function, and additional research is warranted to confirm and further explore these findings.
Asunto(s)
Envejecimiento , Células Sanguíneas/inmunología , Citocinas/inmunología , Caballos/inmunología , Inmunidad Innata , Factores de Edad , Envejecimiento/inmunología , Animales , Células Sanguíneas/fisiología , Citocinas/genética , Escherichia coli/inmunología , Expresión Génica , ARN Mensajero/genética , Rhodococcus equi/inmunologíaRESUMEN
Pneumonia caused by the intracellular bacterium Rhodococcus equi is an important cause of disease and death in immunocompromised hosts, especially foals. Antibiotics are the standard of care for treating R. equi pneumonia in foals, and adjunctive therapies are needed. We tested whether nebulization with TLR agonists (PUL-042) in foals would improve innate immunity and reduce the severity and duration of pneumonia following R. equi infection. Neonatal foals (n = 48) were nebulized with either PUL-042 or vehicle, and their lung cells infected ex vivo. PUL-042 increased inflammatory cytokines in BAL fluid and alveolar macrophages after ex vivo infection with R. equi. Then, the in vivo effects of PUL-042 on clinical signs of pneumonia were examined in 22 additional foals after intrabronchial challenge with R. equi. Foals infected and nebulized with PUL-042 or vehicle alone had a shorter duration of clinical signs of pneumonia and smaller pulmonary lesions when compared to non-nebulized foals. Our results demonstrate that host-directed therapy can enhance neonatal immune responses against respiratory pathogens and reduce the duration and severity of R. equi pneumonia.
Asunto(s)
Infecciones por Actinomycetales , Enfermedades de los Caballos , Caballos , Inmunidad Innata/efectos de los fármacos , Lipopéptidos/farmacología , Oligodesoxirribonucleótidos/farmacología , Neumonía Bacteriana , Rhodococcus equi/inmunología , Receptor Toll-Like 2/agonistas , Receptor Toll-Like 6/agonistas , Receptor Toll-Like 9/agonistas , Infecciones por Actinomycetales/tratamiento farmacológico , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/patología , Infecciones por Actinomycetales/veterinaria , Animales , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/patología , Caballos/inmunología , Caballos/microbiología , Macrófagos Alveolares/inmunología , Macrófagos Alveolares/patología , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/inmunología , Neumonía Bacteriana/patología , Neumonía Bacteriana/veterinaria , Índice de Severidad de la EnfermedadRESUMEN
Rhodococcus equi causes suppurative pneumonia in foals aged 1-3 months; moreover, it has emerged as a pathogenic cause of zoonotic diseases. After the initial report of the ruminant-pathogenic factor VapN encoded by the novel virulence plasmid pVAPN, several reports have described ruminant infections caused by vapN-harboring R. equi. Herein, we conducted a serological epidemiological surveillance in goats at a breeding farm (Farm A) and characterized the vapN-harboring R. equi isolates from this farm. First, we established a simple screening enzyme-linked immunosorbent assay (ELISA) using recombinant glutathione S-transferase-tagged VapN as an immobilized antigen. This method revealed that the VapN antibody titers were elevated in 12 of 42 goats. Subsequently, we attempted to isolate R. equi from the goat feces and soil of Farm A. choE+/vapN+R. equi was isolated from the feces of Goat No. 27 and a soil sample near the shed. The pulsed-field gel electrophoresis (PFGE) patterns of five vapN-harboring R. equi strains isolated from Farm A in 2013 and 2019 were investigated and found to be the same except for the strain (OKI2019F1). However, no difference was observed in VapN expression and growth in macrophages among these vapN-harboring R. equi isolates. Our results revealed that some goats had histories of vapN-harboring R. equi infections, and two genomic types of vapN-harboring R. equi were found in isolates from Farm A. Ruminant-specific (pVAPN-carrying) R. equi might be an unrecognized pathogen in Japan and further studies are required to determine its prevalence and distribution.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Enfermedades de las Cabras/epidemiología , Rhodococcus equi/inmunología , Rhodococcus/inmunología , Infecciones por Actinomycetales/epidemiología , Animales , Anticuerpos Antibacterianos/sangre , Bovinos , Enfermedades de los Bovinos/microbiología , Femenino , Enfermedades de las Cabras/microbiología , Cabras , Japón , Rhodococcus equi/genéticaRESUMEN
BACKGROUND: The bacterium Rhodococcus equi can cause severe pneumonia in foals. The absence of a licensed vaccine and limited effectiveness of commercial R. equi hyperimmune plasma (RE-HIP) create a great need for improved prevention of this disease. HYPOTHESIS: Plasma hyperimmune to the capsular polysaccharide poly-N-acetyl glucosamine (PNAG) would be significantly more effective than RE-HIP at mediating complement deposition and opsonophagocytic killing (OPK) of R. equi. ANIMALS: Venipuncture was performed on 9 Quarter Horses. METHODS: The ability of the following plasma sources to mediate complement component 1 (C1) deposition onto either PNAG or R. equi was determined by ELISA: (1) PNAG hyperimmune plasma (PNAG-HIP), (2) RE-HIP, and (3) standard non-hyperimmune commercial plasma (SP). For OPK, each plasma type was combined with R. equi, equine complement, and neutrophils isolated from horses (n = 9); after 4 hours, the number of R. equi in each well was determined by quantitative culture. Data were analyzed using linear mixed-effects regression with significance set at P < .05. RESULTS: The PNAG-HIP and RE-HIP were able to deposit significantly (P < .05) more complement onto their respective targets than the other plasmas. The mean proportional survival of R. equi opsonized with PNAG-HIP was significantly (P < .05) less (14.7%) than that for SP (51.1%) or RE-HIP (42.2%). CONCLUSIONS AND CLINICAL IMPORTANCE: Plasma hyperimmune to PNAG is superior to RE-HIP for opsonizing and killing R. equi in vitro. Comparison of these 2 plasmas in field trials is warranted because of the reported incomplete effectiveness of RE-HIP.
Asunto(s)
Acetilglucosamina/inmunología , Infecciones por Actinomycetales/veterinaria , Rhodococcus equi/inmunología , Infecciones por Actinomycetales/inmunología , Animales , Anticuerpos Antibacterianos/sangre , Complemento C1/inmunología , Femenino , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Caballos/inmunología , Masculino , Neutrófilos , Plasma/inmunologíaRESUMEN
Prescottella equi (formerly Rhodococcus equi) is a facultative intracellular bacterial pathogen that causes severe pneumonia in foals 1-6â¯months of age, whereas adult horses are highly resistant to infection. We have shown that vaccinating pregnant mares against the conserved surface polysaccharide capsule, ß-1â¯ââ¯6-linked poly-N-acetyl glucosamine (PNAG), elicits opsonic killing antibody that transfers via colostrum to foals and protects them against experimental infection with virulent. R. equi. We hypothesized that equine IgG1 might be more important than IgG4/7 for mediating protection against R. equi infection in foals. To test this hypothesis, we compared complement component 1 (C1) deposition and polymorphonuclear cell-mediated opsonophagocytic killing (OPK) mediated by IgG1 or IgG4/7 enriched from either PNAG hyperimmune plasma (HIP) or standard plasma. Subclasses IgG1 and IgG4/7 from PNAG HIP and standard plasma were precipitated onto a diethylaminoethyl ion exchange column, then further enriched using a protein G Sepharose column. We determined C1 deposition by enzyme-linked immunosorbent assay (ELISA) and estimated OPK by quantitative microbiologic culture. Anti-PNAG IgG1 deposited significantly (Pâ¯<â¯0.05) more C1 onto PNAG than did IgG4/7 from PNAG HIP or subclasses IgG1 and IgG4/7 from standard plasma. In addition, IgG1 from PNAG HIP mediated significantly (Pâ¯<â¯0.05) greater OPK than IgG4/7 from PNAG HIP or IgG1 and IgG4/7 from standard plasma. Our findings indicate that anti-PNAG IgG1 is a correlate of protection against R. equi in foals, which has important implications for understanding the immunopathogenesis of R. equi pneumonia, and as a tool for assessing vaccine efficacy and effectiveness when challenge is not feasible.
Asunto(s)
Acetilglucosamina/inmunología , Infecciones por Actinomycetales/veterinaria , Anticuerpos Antibacterianos/sangre , Complemento C1/inmunología , Inmunoglobulina G/sangre , Fagocitosis , Rhodococcus equi/inmunología , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/prevención & control , Factores de Edad , Animales , Animales Recién Nacidos , Anticuerpos Antibacterianos/clasificación , Anticuerpos Antibacterianos/inmunología , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/prevención & control , Caballos/inmunología , Inmunoglobulina G/clasificación , Proteínas Opsoninas , Neumonía Bacteriana/inmunología , Neumonía Bacteriana/prevención & controlRESUMEN
This chapter describes a strategy for mapping linear B-cell epitopes of proteins using synthetic biotinylated peptides in an ELISA.A set of overlapping peptides were designed based upon a known amino acid sequence of the target protein, VapA (Virulence-associated Protein A) of the bacterium Rhodococcus equi, an important pulmonary pathogen in foals. The peptides synthesized as biotinylated peptides were coated directly onto micro titer plates which had been pre-coated with NeutrAvidin™ and used to screen sera from foals confirmed to have R. equi disease. A linear B-cell epitope was identified which corresponded to a 20 mer sequence of the VapA protein.
Asunto(s)
Proteínas Bacterianas/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Mapeo Epitopo/métodos , Epítopos de Linfocito B/inmunología , Animales , Proteínas Bacterianas/química , Epítopos de Linfocito B/genética , Caballos/inmunología , Caballos/microbiología , Biblioteca de Péptidos , Péptidos/inmunología , Rhodococcus equi/inmunología , Rhodococcus equi/patogenicidadRESUMEN
Rhodococcus equi is a common cause of pneumonia in foals and has extensive clinical, economic and possibly zoonotic consequences. This bacterium survives well in the environment and may be considered as normal flora of adult horses. Certain strains of this bacterium are extremely virulent in foals, and early identification and intervention is crucial for prognosis. Rhodococcus equi is endemic in many parts of the world and occasionally isolated in Israel. This study was designed to evaluate R. equi seroprevalence in adult horses in Israel to indirectly indicate the potential level of exposure of susceptible foals. Sera were collected from 144 horses during spring 2011 and from 293 horses during fall 2014, and the presence of antibodies against virulent R. equi was detected by enzyme-linked immunosorbent assay. Equine seroprevalence of R. equi was found to be 7.6% in 2011 and 5.1% in 2014. Only one farm had seropositive horses in 2011, whereas several farms had seropositive horses in 2014. No significant risk factors for seropositivity were found. Rhodococcus equi appears to be endemic in Israel. This is the first survey of R. equi in Israel that provides information on the epidemiology of this important bacterium.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Anticuerpos Antibacterianos/sangre , Enfermedades de los Caballos/epidemiología , Rhodococcus equi/inmunología , Infecciones por Actinomycetales/epidemiología , Animales , Femenino , Caballos , Israel/epidemiología , Masculino , Estudios SeroepidemiológicosRESUMEN
Rhodococcus equi is the most important causative bacterium of severe pneumonia in foals. We report herein the development of a specific loop-mediated isothermal amplification (LAMP) assay, which targets a gene encoding vapA for detecting virulent R. equi The detection limit of the LAMP assay was 10(4) colony forming units (CFU)/mL, which was equal to 10 CFU/reaction. The clinical efficacy of the LAMP assay was compared with those of 2 published PCR-based methods: nested PCR and quantitative real-time (q)PCR. Agreements between bacterial culture, which is the gold standard for detection of R. equi, and each of the 3 molecular tests were measured by calculating a kappa coefficient. The kappa coefficients of the LAMP (0.760), nested PCR (0.583), and qPCR (0.888) indicated substantial agreement, moderate agreement, and almost perfect agreement, respectively. Although the clinical efficacy of LAMP was not the best among the 3 methods tested, LAMP could be more easily introduced into less well-equipped clinics because it does not require special equipment (such as a thermocycler) for gene amplification. Veterinary practitioners could diagnose R. equi pneumonia more quickly by using LAMP and could use the results to select an appropriate initial treatment.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Enfermedades de los Caballos/diagnóstico , Neumonía Bacteriana/veterinaria , Rhodococcus equi/aislamiento & purificación , Infecciones por Actinomycetales/diagnóstico , Animales , Enfermedades de los Caballos/microbiología , Caballos , Límite de Detección , Técnicas de Amplificación de Ácido Nucleico/veterinaria , Neumonía Bacteriana/diagnóstico , Rhodococcus equi/inmunología , Sensibilidad y EspecificidadRESUMEN
Rhodococcus equi is a respiratory pathogen which primarily infects foals and is endemic on farms around the world with 50% mortality and 80% morbidity in affected foals. Unless detected early and treated appropriately the disease can be fatal. Currently, there is no vaccine available to prevent this disease. For decades researchers have endeavoured to develop an effective vaccine to no avail. In this study a novel human adenoviral vector vaccine for R. equi was developed and tested in the mouse model. This vaccine generated a strong antibody and cytokine response and clearance of R. equi was demonstrated following challenge. These results show that this vaccine could potentially be developed further for use as a vaccine to prevent R. equi disease in foals.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Vacunas Bacterianas/uso terapéutico , Enfermedades de los Caballos/prevención & control , Rhodococcus equi/inmunología , Infecciones por Actinomycetales/prevención & control , Animales , Anticuerpos Antibacterianos/inmunología , Vacunas Bacterianas/inmunología , Citocinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Enfermedades de los Caballos/microbiología , Caballos , Pulmón/citología , Pulmón/metabolismo , Pulmón/microbiología , Ratones , Ratones Endogámicos C3HRESUMEN
Since a vaccine is not available against Rhodococcus equi, R equi-specific hyperimmune plasma (HIP) is commonly used, although its efficacy remains controversial. The objective of this study was to evaluate the ability of a commercially available HIP to prevent clinical rhodococcal pneumonia in neonatal foals after experimental challenge.
Asunto(s)
Animales Recién Nacidos/inmunología , Enfermedades de los Caballos/prevención & control , Plasma/inmunología , Neumonía Bacteriana/veterinaria , Rhodococcus equi/inmunología , Animales , Animales Recién Nacidos/sangre , Anticuerpos Antibacterianos/sangre , Ensayo de Inmunoadsorción Enzimática/veterinaria , Caballos , Neumonía Bacteriana/prevención & control , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
Rhodococcus equi is a common cause of pneumonia in young foals worldwide and has considerable economic effects on the global equine industry. Despite ongoing efforts, no vaccine is currently available to prevent rhodococaal pneumonia. This is due, in part, to an incomplete understanding of the protective immune response to this bacterium. While antibodies to VapA, a lipoprotein produced by virulent R. equi, are useful in differentiating antibody production in response to pathogenic versus non-pathogenic strains, the significance of the humoral response of foals to this lipoprotein remains poorly defined. The objectives of this study were to evaluate changes in VapA-specific IgG and IgG subclasses after exposure and infection of neonatal foals. Experimental foals included those challenged with R. equi at 1 (n=18), 2 (n=4) and 3 (n=6) weeks of age. Confirmed naturally infected (n=7) and not infected (n=3) foals were also included. All foals were bled 24h after birth and weekly thereafter for a period of 8 weeks. Antibody changes over time were evaluated. Following birth, VapA-specific IgGs significantly (p<0.05) decreased over time in all foals as a result of normal decay of passively transferred antibodies. Both VapA-specific IgGa and IgG(T) significantly increased (p<0.05) after experimental challenge, however, the rise in IgG(T) occurred earlier. Only a significant (p<0.05) increase in VapA-specific IgG(T) over time was seen after natural infection. Whether VapA-specific IgG(T) can be used to differentiate rhodococcal from other pneumonias requires further investigation under field conditions.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Proteínas Bacterianas/inmunología , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Rhodococcus equi/inmunología , Rhodococcus equi/patogenicidad , Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/prevención & control , Animales , Animales Recién Nacidos , Anticuerpos Antibacterianos/sangre , Anticuerpos Antibacterianos/clasificación , Especificidad de Anticuerpos , Proteínas Bacterianas/genética , Enfermedades de los Caballos/prevención & control , Caballos , Inmunidad Humoral , Inmunoglobulina G/sangre , Inmunoglobulina G/clasificación , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Rhodococcus equi/genética , Virulencia/inmunologíaRESUMEN
α-GalCer is a potent immunomodulatory molecule that is presented to NKT cells via the CD1 antigen-presenting system. We hypothesized that when used as an adjuvant α-GalCer would induce protective immune responses against Rhodococcus equi, an important pathogen of young horses. Here we demonstrate that the equine CD1d molecule shares most features found in CD1d from other species and has a suitable lipid-binding groove for presenting glycolipids to NKT cells. However, equine CTL stimulated with α-GalCer failed to kill cells infected with R. equi, and α-GalCer did not increase killing by CTL co-stimulated with R. equi antigen. Likewise, α-GalCer did not induce the lymphoproliferation of equine PBMC or increase the proliferation of R. equi-stimulated cells. Intradermal injection of α-GalCer in horses did not increase the recruitment of lymphocytes or cytokine production. Furthermore, α-GalCer-loaded CD1d tetramers, which have been shown to be broadly cross-reactive, did not bind equine lymphocytes. Altogether, our results demonstrate that in contrast to previously described species, horses are unable to respond to α-GalCer. This raises questions about the capabilities and function of NKT cells and other lipid-specific T lymphocytes in horses.
Asunto(s)
Galactosilceramidas/inmunología , Caballos/inmunología , Activación de Linfocitos/inmunología , Células T Asesinas Naturales/inmunología , Adyuvantes Inmunológicos/química , Adyuvantes Inmunológicos/farmacología , Secuencia de Aminoácidos , Animales , Antígenos CD1d/química , Antígenos CD1d/genética , Antígenos CD1d/inmunología , Células Cultivadas , Galactosilceramidas/química , Galactosilceramidas/farmacología , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/microbiología , Caballos/genética , Caballos/microbiología , Interacciones Huésped-Patógeno/inmunología , Humanos , Activación de Linfocitos/efectos de los fármacos , Ratones , Modelos Moleculares , Datos de Secuencia Molecular , Estructura Molecular , Células T Asesinas Naturales/metabolismo , Filogenia , Estructura Terciaria de Proteína , Rhodococcus equi/inmunología , Rhodococcus equi/fisiología , Homología de Secuencia de AminoácidoRESUMEN
Rhodococcus equi is the most common cause of pneumonia in young foals. A vaccine is not available and the use of R equi-specific hyperimmune plasma (HIP) is common. Despite its widespread use, the efficacy of HIP in preventing disease remains controversial. The objectives of this study were (1) to evaluate the virulence associate protein A (VapA)-specific IgG and IgG subclasses in commercially available R equi HIP and (2) to evaluate serum VapA-specific IgG and IgG subclasses in foals following administration of commercial R equi HIP. Three different lots from four commercial R equi HIP were sampled. VapA-specific IgG and IgG subclasses were evaluated in all samples using an ELISA. Serum was collected from newborn foals either after commercial R equi HIP was administered (n=97) or not (n=70). Serum was also collected from each mare. Administration of HIP significantly (P<0.001) increased VapA-specific IgGs in recipient foals, however, there was a marked variation in VapA-specific IgGs in foals receiving the same product. VapA-specific IgGs were significantly different (P<0.001) between products and varied between lots, with coefficients of variation ranging from 17 to 123 per cent. These results may explain previously reported disparities in HIP efficacy.
Asunto(s)
Animales Recién Nacidos/inmunología , Proteínas Bacterianas/inmunología , Enfermedades de los Caballos/prevención & control , Inmunoglobulina G/sangre , Plasma/inmunología , Rhodococcus equi/inmunología , Factores de Virulencia/inmunología , Animales , Animales Recién Nacidos/sangre , Anticuerpos Antibacterianos/sangre , Proteínas Bacterianas/sangre , Ensayo de Inmunoadsorción Enzimática/veterinaria , Femenino , Caballos , Neumonía Bacteriana/prevención & control , Neumonía Bacteriana/veterinaria , Factores de Virulencia/sangreRESUMEN
Rhodococcus equi is an important pathogen of foals that causes severe pneumonia. To date, there is no licensed vaccine effective against R. equi pneumonia of foals. The objectives of our study were to develop an electron beam (eBeam) inactivated vaccine against R. equi and evaluate its immunogenicity. A dose of eBeam irradiation that inactivated replication of R. equi while maintaining outer cell wall integrity was identified. Enteral administration of eBeam inactivated R. equi increased interferon-γ production by peripheral blood mononuclear cells in response to stimulation with virulent R. equi and generated naso-pharyngeal R. equi-specific IgA in newborn foals. Our results indicate that eBeam irradiated R. equi administered enterally produce cell-mediated and upper respiratory mucosal immune responses, in the face of passively transferred maternal antibodies, similar to those produced in response to enteral administration of live organisms (a strategy which previously has been documented to protect foals against intrabronchial infection with virulent R. equi). No evidence of adverse effects was noted among vaccinated foals.
Asunto(s)
Infecciones por Actinomycetales/veterinaria , Vacunas Bacterianas/uso terapéutico , Enfermedades de los Caballos/inmunología , Caballos/inmunología , Inmunidad Activa , Infecciones por Actinomycetales/prevención & control , Animales , Rhodococcus equi/inmunología , Rhodococcus equi/ultraestructuraRESUMEN
This study aimed to determine the effectiveness of a pregnant mare immunization of a Rhodococcus equi (R. equi) vaccine candidate containing a water-based nanoparticle mineral oil adjuvanted (Montanide IMS 3012) inactive bacterin and virulence-associated protein A (VapA), as well as the administration of anti-R. equi hyperimmune (HI) plasma against R. equi challenge in the mares' foals. The efficacy of passive immunizations (colostral passive immunity by mare vaccination and artificial passive immunity by HI plasma administration) was evaluated based on clinical signs, complete blood count, blood gas analysis, serological response (ELISA), interleukin-4 (IL-4) and interferon gamma (IFN- γ ), total cell count of the bronchoalveolar lavage fluids (BALF) samples, reisolation rate of R. equi from BALF samples (CFU/mL), lung samples (CFU/gr), and lesion scores of the organs and tissue according to pathological findings after necropsy in the foals. The vaccination of pregnant mares and HI plasma administration in the foals reduced the severity of R. equi pneumonia and lesion scores of the organs and tissue by 3.54-fold compared to the control foals. This study thus indicates that immunization of pregnant mares with R. equi vaccine candidate and administration of HI plasma in mares' foals effectively protect foals against R. equi challenge.
Asunto(s)
Infecciones por Actinomycetales/inmunología , Infecciones por Actinomycetales/prevención & control , Anticuerpos Antibacterianos/sangre , Rhodococcus equi/inmunología , Rhodococcus equi/patogenicidad , Animales , Anticuerpos Antibacterianos/administración & dosificación , Femenino , Caballos , VacunaciónRESUMEN
The pathogenic actinomycete Rhodococcus equi causes severe purulent lung infections in foals and immunocompromised people. Although relatively unsusceptible to R. equi, mice are widely used for in vivo studies with this pathogen. The most commonly employed mouse model is based on systemic (intravenous) infection and determination of R. equi burdens in spleen and liver. Here, we investigated the murine lung for experimental infection studies with R. equi. Using a 10(7)CFU intranasal challenge in BALB/c mice, virulent R. equi consistently survived in quantifiable numbers up to 10 days in the lungs whereas virulence-deficient R. equi bacteria were rapidly cleared. An internally controlled virulence assay was developed in which the test R. equi strains are co-inoculated and monitored in the same mouse. Isogenic R. equi bacteria lacking either the plasmid vapA gene or the entire virulence plasmid were compared using this competitive assay. Both strains showed no significant differences in in vivo fitness in the lung, indicating that the single loss of the virulence factor VapA was sufficient to account for the full attenuation seen in the absence of the virulence plasmid. To test the adequacy of the lung infection model for monitoring R. equi vaccine efficacy, BALB/c mice were immunized with live R. equi and challenged intranasally. Vaccination conferred protection against acute pulmonary challenge with virulent R. equi. Our data indicate that the murine lung infection model provides a useful tool for both R. equi virulence and vaccine studies.